<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">


Press Releases

Our latest announcements

Biodesix to Participate in Two Upcoming Investor Conferences in September

Biodesix to participate at Morgan Stanley 20th Annual Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference

Canaccord Genuity 42nd Annual Growth Conference

Rewatch the live fireside chat during Canaccord Genuity 42nd Annual Growth Conference, featuring Scott Hutton, CEO of Biodesix Inc.

Biodesix Named a Top 100 Healthcare Technology Company of 2022

Biodesix is recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022.

Biodesix Announces Second Quarter 2022 Results and Highlights

Biodesix, Inc. (Nasdaq: BDSX) announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.

Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.

Biodesix to Present Data at IASLC 2022 World Conference...

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

Biodesix announced today that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4

Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

Adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment

Biodesix Obtains Medicare Coverage for Nodify CDT® Lung Nodule Test

The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.

Biodesix Announces Research Agreement with Top US Cancer Center

Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.

1 2 3 4 5 6 7 8 9 Last